Precision Navigation: Active and Passive Targeting Strategies of Nanocarriers

0:00Welcome to Creative Biolabs' podcast channel. Join us as we explore the cutting-edge science of targeted delivery systems that are revolutionizing medicine. Interested in the future of drug development? Subscribe now! Welcome back to the Pharma Frontier. I'm Alex. Last time, we explored with Dr. Lena Cruz how nanocarriers load and release drugs like intelligent capsules. Today, we tackle a key question. How do these capsules navigate the complex human body to precisely find and enter tumor cells? This is the Art of Targeting. Lena, welcome back. Thanks, Alex. Targeting is indeed the central goal of nanomedicine design. We want anti-cancer drugs to specifically localize to a particular tissue, cell type, or disease state while minimizing or eliminating damage to healthy tissue. That sounds extremely challenging. Are there any successful precedents?

1:00Yes. A famous example of molecular targeting is Novartis's drug amatinib or Gleevec. It's a tyrosine kinase inhibitor for chronic myeloid leukemia. The cancer cells in this disease have a characteristic gene mutation producing an abnormal kinase. Gleevec directly targets and inhibits the specific mutant kinase like a custom-made key for one lock. This raised the five-year survival rate of patients from 33% to 89%. That's a miraculous drug. But that's a small molecule drug working directly. For nanocarriers, what's different about their targeting strategy? You're right, Gleevec is inherently targeted. For nanocarriers, we typically endow them with two targeting capabilities, passive and active. Let's start with passive targeting. This relies primarily on the enhanced permeability and retention effect, or EPR effect, which we discussed in part one.

2:01That's exploiting the leaky tumor blood vessels and poor lymphatic system to let nanoparticles passively accumulate there. Exactly. The EPR effect is the physical foundation that allows nanomedicines to concentrate in tumor tissue. It's an organ level, passive targeting, it doesn't distinguish between cancer cells and normal cells within the tumor stroma, but it does concentrate more drug in the tumor region. So how do we further distinguish tumor cells from normal cells? That requires active targeting, right? Yes. Active targeting involves installing a homing device on the nanocarrier. This is a ligand that binds specifically to receptors or markers overexpressed on the surface of tumor cells. This provides chemical level recognition, achieving cellular or even subcellular specificity. What are these homing devices usually? There are many types. They can be short peptides, like the CRGD peptide,

3:03which targets integrin receptors over expressed on many tumor cells. It can be folic acid because many tumor cells express far more folate receptors than normal cells. They can also be antibodies or their fragments, which specifically recognize unique proteins on cancer cell surfaces. For example, herceptin for breast cancer targets the human epidermal growth factor receptor 2. You attach the antibody directly to the nanoparticle? Yes, such drug delivery systems are called immunomacells or immunolyposomes. One of the most important advantages of nanoparticles is their ability to display multiple. Numerous ligands on a single particle surface through active targeting. What's the benefit of displaying multiple ligands? This introduces a crucial concept, multivalency. In nature, biological recognition, adhesion, and signaling often occur through multivalent or multipoint interactions. A single ligand binding to its receptor might be weak.

4:08But if you densely pack dozens or even hundreds of the same ligand on one nanoparticle, they can simultaneously bind to multiple receptors on the cell surface. This collective binding strength, which we call avidity, becomes very strong, far exceeding the simple sum of individual interactions. So it's like using many small magnets to attract a piece of iron, better and stronger than one big magnet? A very apt metaphor. Multivalency not only enhances binding strength but can also improve selectivity. Even if each individual ligand has low affinity for its receptor, the powerful avidity generated by multivalent display can make the nano carrier preferentially bind to cells that densely express those receptors, like cancer cells, over normal cells with sparse receptors. That's brilliant using quantity to compensate for individual quality and achieve specificity. Beyond ligands, the nanoparticle size and surface directly affect its fate, correct?

5:08Absolutely. We mentioned earlier that 40 to 200 nanometers is ideal. Surface properties, especially the stealth coating like polyethylene glycol, are crucial for avoiding rapid clearance by the immune system. This process is avoiding optimization. Immune cells add sore plasma proteins onto the particle surface and then engulf them. PE dilation, by forming a hydrophilic shield, reduces protein absorption, extends blood circulation time, and creates the opportunity for both passive and active targeting. But couldn't PE dilation interfere with drug release or the function of the targeting ligand? That's a good question of balance. Overly dense or long PEG chains can indeed create steric hindrance, impeding drug release or ligand receptor binding. Therefore, there is now research into shedible PEG. It provides protection during circulation but detaches in the tumor microenvironment,

6:09exposing the inner drug or targeting ligands. It seems every design detail requires careful trade-offs. Back to targeting. How to actively targeting ligands help the particle get inside the cell? When the nanoparticle binds to a cell surface receptor via its ligand, it typically triggers the cells and a cytosis mechanism. The cell membrane invaginates, wrapping the entire particle into a small vesicle called an endosome and bringing it inside. This successfully transports the drug into the cell, overcoming the cell membrane barrier. So, the targeting ligand is not only responsible for recognition but also for calling the cells transport team to bring the cargo inside. Precisely. Without targeting ligands, nanoparticles might just randomly adhere to the cell surface or be taken up very inefficiently. With active targeting, the efficiency of endocytosis is greatly enhanced, ensuring the therapeutic payload is effectively delivered inside the cell to where it needs to act.

7:12Lena, our discussion today really highlights how targeting transforms a nanoparticle from a passive passenger to an active hunter. It makes me wonder, does the choice of core material, whether it's a polymer myself, a dendromer, or something else influence which targeting strategy is best or how well it works? That's a very insightful question, Alex. The short answer is yes, significantly. Different materials offer different canvases for attaching targeting ligands. For example, the dense, multivalent surface of a dendromer is perfect for presenting many copies of a small molecule ligand, like folate, leveraging that multivalent effect we talked about. On the other hand, a liposome or a polymeric myself might have a more fluid surface, which could be ideal for incorporating larger targeting moieties like whole antibodies without affecting their structure. Also, the materials own inherent properties, like charge or natural affinity for certain proteins, can interact with the targeting strategy, sometimes requiring

8:15careful design to avoid the ligand being hidden or hindered. So the material isn't just a passive container, it actively shapes the carrier's identity and capabilities, including how it navigates. Precisely. You can't separate the what it's made of from the what it does. The material dictates the possible architecture, the loading capacity, the release profile, and the presentation of the targeting system. It's all part of an integrated design. That sets the stage perfectly for our final tour of the material library next time. Understanding the materials will complete our picture of how these incredible systems are built from the ground up. Thanks for that preview, Lena.